Effectiveness and side effects of thiazolidinediones for type 2 diabetes

• Endocrinology and Obstetric Medicine, Mater Hospital, Raymond Terrace, Sth Brisbane, QLD 4101.

---

• 1. Hussein Z, Wentworth JM, Nankervis AJ, et al. Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital. Med J Aust 2004; 181: 536-539. <eMJA full text>
• 2. Roy R, Navar M, Palomeno G, Davidson MB. Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulfonylurea agent: a systematic evaluation of triple oral therapy in a minority population. Diabetes Care 2004; 27: 1741-1742.
• 3. Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med 2004; 116: 230-235.
• 4. Dailey GE 3rd, Noor MA, Park JS, et al. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med 2004; 116: 223-229.
• 5. Kiayias JA, Vlachou ED, Theodosopoulou E, Lakka-Papadodima E. Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients. Diabetes Care 2002; 25:1251-1252.
• 6. Byrne J, Garg S, Vaidya A, et al. Efficacy of triple combination oral hypoglycaemic therapy using rosiglitazone, metformin and sulphonylurea in lowering HbA1c. Pract Diabet Int 2003; 20: 58-60.
• 7. Yale JF, Valiquett TR, Ghazzi MN, et al. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134: 737-745.
• 8. Bell DS, Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr Pract 2002; 8: 271-275.